Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.

A Lemay, R Maheux, Rodolphe Maheux, C Jean, Nacia Faure, N Faure
Progress in clinical and biological research · 1986 · vol. 225 , pp. 157–73 · PMID:3097663 · W2404688841
article OA: closed CC0 ⤵ 2 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated how different administration methods of buserelin, an LHRH agonist, affect pituitary-ovarian axis suppression for endometriosis treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Ovary Pituitary Gland Administration, Intranasal Buserelin Buserelin Buserelin Endometriosis Endometriosis Endometrium Endometrium Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Injections, Subcutaneous Luteinizing Hormone

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:40.384591+00:00
License: CC0 · commercial use OK